As such, targeting GLT1D1 could be a novel strategy to combat PD‐L1/PD‐1 interaction‐mediated immunosuppression in B‐NHLs and could potentially increase the clinical outcome of lymphoma patients. This evidence concerns the gene CD274 and lymphoma.